Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine switch study for antidepressant discontinuation withdrawal
jRCT1031260497Active, not recruiting
- Sponsor
- SUSUMU HIROTA
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vortioxetine in major depressive disorder (MDD) and anxiety disorder, sponsored by SUSUMU HIROTA. Primary endpoint: Successful maintenance of antidepressant-free state after vortioxetine discontinuation. Started Dec 2025; status: active, not recruiting.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on jRCT1031260497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031260497.